Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
NCT05837689
·
clinicaltrials.gov ↗
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
DRUG:
Blinatumomab
Sponsor
Xiaojun Xu